Benzinga | Sep 10, 2020 08:09AM EDT

Bionano Genomics Highlights Adoption Of Saphyr By Three Pediatric Hospitals In Europe

SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that its Saphyr system has been adopted through reagent-rental agreements by three renowned institutions in Spain, Italy and France: Ni?o Jes?s University Children's Hospital in Madrid; Ospedale Pediatrico Bambino Ges? in Rome; and Necker--Enfants Malades Hospital in Paris. The three children's hospitals aim to assess Saphyr's potential for use in diagnosing childhood leukemias versus current standards of care, including karyotyping, chromosomal microarray and FISH.



"We are thrilled to have these leading healthcare institutions incorporate Saphyr into their practices. We believe their use and adoption of Saphyr through reagent-rental agreements is an important validation of our technology and a significant milestone for us as we aim to make Saphyr an essential component of the future of cytogenomic analysis of leukemias and solid tumors," said Erik Holmlin, PhD, Chief Executive Officer of Bionano. "Receiving a diagnosis of childhood leukemia is devastating for parents and families, and a comprehensive, fast and accurate molecular analysis of the genomic changes in the cancer cells can help doctors prescribe the most optimal therapies and contribute to faster patient recovery. With leading key opinion leaders at each institution using our technology to develop new diagnostics, we view this as a critical step towards improving outcomes for children with cancer worldwide."

To date, Bionano has successfully driven adoption of its Saphyr system throughout some of the largest markets for medical research in Europe, including Germany, France, U.K. and Benelux. Based on the company's track record of providing comprehensive assessments of leukemia via genome imaging, Bionano is now selling Saphyr in additional European markets. Through this expansion, Saphyr will be utilized in cutting edge clinical development programs at each adopting institution in an effort to replace traditional cytogenetic technologies.